TABLE 2.
Levothyroxine use and risk of cancer
| Cancer types |
Cases (n = 601 733) Exposed/Unexposed |
Control (n = 2 406 932) Exposed/Unexposed |
Unadjusted odds ratio (95% CI) | P‐value | Adjusted odds ratio a (95% CI) | P‐value |
|---|---|---|---|---|---|---|
| Overall | 6535/595 198 | 16 789/2 390 143 | 1.57 (1.52‐1.61) | <.0001 | 1.50 (1.46‐1.54) | <.0001 |
| Esophageal | 34/11 140 | 164/44 532 | 0.83 (0.57‐1.20) | .31 | 0.80 (0.55‐1.17) | .24 |
| Gastric | 180/22 394 | 582/89 714 | 1.24 (1.05‐1.47) | .01 | 1.19 (1.00‐1.42) | .05 |
| Colorectal | 723/85 874 | 2432/343 956 | 1.19 (1.10‐1.30) | .001 | 1.14 (1.05‐1.24) | .001 |
| Liver | 506/80 701 | 1897/322 931 | 1.07 (0.97‐1.18) | .19 | 0.98 (0.88‐1.10) | .76 |
| Pancreatic | 109/10 037 | 311/40 273 | 1.41 (1.13‐1.76) | .002 | 1.27 (1.01‐1.60) | .03 |
| Lung | 581/67 828 | 1822/271 814 | 1.28 (1.16‐1.40) | <.0001 | 1.22 (1.11‐1.35) | <.0001 |
| Skin | 143/15 637 | 393/62 727 | 1.46 (1.21‐1.77) | <.0001 | 1.42 (1.17‐1.72) | <.0001 |
| Female Breast | 916/64 575 | 2991/258 973 | 1.23 (1.14‐1.32) | <.0001 | 1.24 (1.15‐1.33) | <.0001 |
| Cervical | 126/15 010 | 693/59 851 | 0.72 (0.60‐0.88) | .0009 | 0.75 (0.62‐0.91) | .003 |
| Prostate | 168/32 251 | 516/129 160 | 1.30 (1.09‐1.55) | .002 | 1.26 (1.06‐1.50) | .01 |
| Bladder | 161/19 373 | 498/77 638 | 1.30 (1.08‐1.55) | .004 | 1.23 (1.02‐1.47) | .02 |
| Kidney | 134/14 865 | 421/59 575 | 1.28 (1.05‐1.55) | .01 | 1.15 (0.93‐1.41) | .18 |
| Brain | 110/7560 | 225/30 455 | 1.98 (1.57‐2.49) | <.0001 | 1.90 (1.48‐2.44) | <.0001 |
Abbreviation: CI, confidence interval.
a
Odds ratio adjusted for age, gender, comorbid conditions, age‐adjusted CCI scores, and other drugs in Table 1.